Introduction {#S1}
============

It is remarkable to consider that human immunodeficiency virus type 1 (HIV-1) has caused a global pandemic despite being quite poorly transmissible, with the chance of an HIV-infected, treatment-naive individual passing the virus to their partner through penile-vaginal sex being a fraction of one percent ([@B94]; [@B32]). The explanation for this apparent contradiction is that multiple factors can enhance the likelihood of transmission, including the type of mucosa exposed to virus during sex, the viral titer in the anogenital secretions of the infected partner, and the presence/number of CD4 receptor-expressing target cells in the mucosa of the uninfected partner ([@B94]; [@B26]). When viewed through this lens, it becomes clear why sexually transmitted infections (STIs) might facilitate HIV-1 transmission, either directly through their effect on viral replication or indirectly through the inflammation-mediated recruitment of lymphocytes and/or disruption of the mucosal barrier. While a variety of co-infections can influence HIV-1 transmission ([@B30]; [@B51]), this review will focus on the effects of *Neisseria gonorrhoeae*, both because gonococcal infection markedly enhances HIV-1 transmission at an epidemiological level ([@B30]; [@B16]) and because a number of studies have explored the molecular and immunologic aspects of this synergy. When these studies are considered together, the complexity of the association between these pathogens starts to become clear, even though there are apparently contradictory findings depending upon the models used to explore this pathogen interaction. Herein, we will review the replication cycle of HIV-1 and consider the possible impact of *N. gonorrhoeae* infection. Then, we will attempt to integrate these research findings to generate a model that can be used to understand the outcome of this common co-infection, providing a framework to direct future research and a guide for ongoing attempts to intervene.

HIV-1 Infection {#S2}
===============

Despite significant global efforts to control HIV-1 transmission, the virus continues to be a scourge, particularly in high risk populations that include men who have sex with other men (MSM) and female sex workers. Acute HIV-1 infection is characterized by a transient period of very high titer viremia that lasts for just a few weeks, which is followed by a chronic infection phase characterized by a much lower viral load in both blood and anorectal secretions once a host adaptive immune response has been generated. However, HIV-1 infection is lifelong, due in equal parts to the virus's ability to integrate its genome into the chromosomal DNA of long-lived CD4+ memory T cells where it can reside undetected, while simultaneously evading the adaptive response during active replication by mutating its genome at a phenomenal rate \[4 × 10^--3^ per base per cell, the highest for any described biological entity ([@B20])\]. For the latently infected cell, subsequent immune activation driven by infectious or other inflammatory stimuli will cause the virus to exit latency and initiate active replication resulting in viral propagation and eventual death of the infected cell. Over an average of 8--10 years, a combination of active cellular viral replication and bystander CD4+ T cell death leads to gradual depletion of blood CD4+ T-cell numbers, along with persistent immune activation and CD8+ T cell exhaustion and dysfunction, with irreparable damage to the structure of secondary lymphoid organs preventing recovery of depleted CD4+ T-cell counts. Once the blood CD4+ T cell count falls below ∼200 cells/ml, this is now classified as acquired immunodeficiency syndrome (AIDS), and the immune system is now unable to protect the infected individual against a variety of opportunistic infections and neoplasms \[for review see [@B56]\].

Fortunately, HIV-1 is now a manageable chronic infection thanks to the development of antiretroviral compounds that target multiple different points of the viral life cycle. Combination antiretroviral therapy (cART) utilizes a combination of several of these compounds (generally 2--3 separate medications) to simultaneously block multiple stages of the viral life cycle and permit recovery of the immune system. Successful treatment suppresses virus replication to virtually undetectable level, restoring an individual's life expectancy to near-normal ([@B6]). However, while effective at preventing HIV-1 replication, these medications are not a cure since the latent HIV reservoir remains unaffected by the treatment. Because of this, interruption of therapy consistently and predictably leads to the rebound of viral replication in blood, and the patient will progress to AIDS if medication is not continued. However, while the infected individual cannot be cured, the remarkable efficacy of cART is such that HIV-infected individuals who are compliant with their medication and maintain a suppressed viral load are considered to be non-infectious to their sexual partners ([@B17]; [@B92]).

By halting transmission, cART has contributed to a slow reduction in the global incidence of new HIV-1 infections ([@B106]). However, the administration of therapy is costly, and some HIV-1 infected individuals do not have access to these drugs -- this is particularly true within marginalized key populations such as MSM and female sex workers ([@B61]; [@B8]). According to UNAIDS ([@B106]), there were 37.9 million people living with HIV-1 globally in 2018, with 23.3 million (61%) of these individuals on antiretroviral therapy. Indeed, the combination of ongoing HIV transmission by untreated (or inappropriately treated) individuals, together with the greatly enhanced survival of infected individuals taking antiretroviral treatment (ART), means that there is a steady increase in the global prevalence of HIV-1 each year; globally, with a 23% increase between 2010 and 2018 ([@B106]). The clear message is that the only way to reduce the global burden of HIV-1 is to develop new and better interventions to reduce HIV-1 transmission and/or to develop feasible strategies for HIV cure.

HIV-1 Transmission {#S3}
==================

Human immunodeficiency virus type 1 transmission risk varies greatly between populations, with heterogeneity linked to multiple behavioral and biological factors that include socioeconomic status, race, sexual partner numbers and patterning, mucosal site of exposure, circumcision status and contraceptive use, the presence of anogenital infections and the mucosal microbiome. Exposure of the anorectal mucosa to HIV through receptive anal intercourse remains the highest risk sexual behavior for HIV-1 transmission ([@B84]), with an incidence that averages 138 per 10,000 exposures. In comparison, the rates of transmission during penile-vaginal sex are approximately ten-fold lower, averaging 8 and 4 cases per 10,000 coital acts for male-to-female and female-to-male transmission, respectively ([@B84]). However, clinical and epidemiological studies have clearly established that HIV-1 transmission risk is substantially and consistently increased in the presence of certain co-infecting bacterial, viral and fungal pathogens ([@B32]) or inflammatory mucosal microbiota ([@B7]; [@B77]; [@B97]). In each case, the mucosal immune milieu is altered in response to these microbial challenges in a way that damages epithelial integrity and enhances HIV-1 shedding (in the infected partner) and access to preferred viral target cells in the uninfected partner, namely activated mucosal CD4^+^ helper T-cells.

In considering how anogenital co-infections may influence HIV-1 transmission, it is important to differentiate between effects that alter the *infectiousness* of the infected partner versus those that influence the uninfected partner's *susceptibility* to infection ([@B32]). Given that the HIV-1 titer in genital secretions dictates the likelihood of transmission from an infected person ([@B88]), infectiousness will be increased by any factor that increases virus shedding in genital mucus or semen, or perhaps that selects for viral variants that are inherently better able to establish infection. Synergistically in the uninfected partner, susceptibility to infection will be increased by any host-intrinsic factors that provide portals of entry across the mucosal barrier, since this provides access to target CD4+ T cells in the underlying tissues, or that stimulate an immune response that is either ineffective at combatting or, even worse, that promotes HIV-1 replication ([@B32]). For example, a co-infecting pathogen may increase an HIV-infected person's infectiousness by stimulating an immune response that recruits virally infected cells to the genital tract and/or by increasing viral production by HIV-infected cells that are already resident there ([Figure 1](#F1){ref-type="fig"}). Alternatively, mucosal tissue barrier function may be hampered by direct pathogen-induced cytolysis of epithelial cells and/or indirectly by the disruption of epithelial cell junctions in response to inflammatory cytokines elicited by a co-infecting pathogen, increasing an individual's susceptibility by allowing HIV-1 entry into the underlying tissues ([Figure 2](#F2){ref-type="fig"}).

![Impact of *Neisseria gonorrhoeae* infection on HIV production and shedding in an already HIV infected person. The presence of the gonococci within the urogenital tract results in an exuberant neutrophil response that is characterized by increased presence of pro-inflammatory cytokines and chemokines. This results in the recruitment of infected CD4 T-cells to the area of gonococcal infection, leading to activation of the latent HIV and release of virions to the genital microenvironment. This event could also result in infection of HIV-uninfected but gonococcal-activated CD4 T-cells and further propagation of the virus within the patient. Macrophage and dendritic cells (DCs) may also take up the virus to be presented to CD4 T-cells in distal lymphoid organs, increasing the efficiency of CD4 T cell infection and causing further propagation of infection, ultimately leading to destruction of secondary lymphoid organs. Following gonococcus-induced disruption of the epithelial barrier, either directly by the bacterium or through the inflammatory milieu, the cell free HIV particles may be released freely into the genital lumen to increase infectious potential of this HIV infected individual.](fmicb-11-01299-g001){#F1}

![Impact of *Neisseria gonorrhoeae* infection on establishment of HIV infection in a seronegative individual. The gonococcus may cause an increased susceptibility to HIV infection through a combination of the inflammation-induced damage of the epithelial barrier and increased inflammation within the genital microenvironment. This allows enhanced entry of HIV into the submucosa, either through dendritic cells (DCs) that are sampling the mucosal environment or through disrupted epithelium. Given that the gonococci cause an intense localized inflammation, as evidenced by an extensive neutrophil influx to the site of infection, CD4 T-cells that are recruited to the site of infection will be activated by the cytokines and other inflammatory mediators so as to become optimal targets for HIV infection and replication. Macrophage that are recruited to the site of gonococcal infection may also produce pro-inflammatory cytokines and chemokines to simultaneously activate local CD4 T-cells and recruit further HIV-receptive target cells. Furthermore, the macrophages or DCs can take up the HIV present in the genital microenvironment and travel to distal secondary lymphoid organs where they can further promote HIV infection of CD4 T-cells in these regions.](fmicb-11-01299-g002){#F2}

HIV-1 Biology {#S4}
=============

While the intact mucosa typically provides an effective barrier against HIV-1, the virus may normally gain access to underlying target cells via its transcellular transport from the mucosal lumen into the lamina propria through intact epithelial cells, may pass through an non-intact epithelium that has been disrupted by inflammation or by physical stress during sexual activity, or may be taken up by tissue resident dendritic cells (DCs) in the lamina propria as they extend dendrites between epithelial cells to sample the luminal microenvironment for foreign antigens ([@B105]). Once within the mucosal tissues, activated CD4+ T cells are the primary target for HIV-1 infection. However, other cell types can either directly or indirectly facilitate infection. Most notable in this regard, DCs may express DC-SIGN, a cell surface-expressed receptor that binds the HIV-1 envelope glycoprotein, gp120 ([@B35]). This interaction does not lead to direct DC infection, but the DC may transfer the virus to T cells with which it engages *in trans*, either within the mucosal tissue microenvironment or after the DC migrates into secondary lymphoid organs ([@B98]). Macrophages can also take up cell-free virus and present it to CD4+ T cells. While macrophages are considered to be intrinsically resistant to HIV-1 infection, they clearly can be infected by HIV-1 since integrated virus is apparent and has been demonstrated within them ([@B4]; [@B15]). The contribution of these cell types to infection, and the effect that *N. gonorrhoeae* may have on HIV exposure and the outcome of this interaction, will be discussed further below.

Upon contact with CD4+ T cells, the homotrimeric HIV-1 envelope protein (Env) engages cell surface-expressed CD4 and one of its co-receptors, generally either the CXCR4 or CCR5 chemokine receptor, depending on the viral variant's tropism. This interaction promotes a dramatic conformational change in Env to drive fusion of the HIV-1 and target cell membranes, allowing entry of the viral core into the cytoplasm ([@B91]). Once uncoated, the single-stranded RNA genome is reverse transcribed to double-stranded DNA by the pre-formed viral reverse transcriptase; this is a prerequisite for viral genome transport into the nucleus and its integration into the host cell genome. Integration allows establishment of a durable yet transcriptionally silent viral reservoir within long-lived memory T-cells ([@B28]; [@B14]). However, cellular activation promotes HIV-1 exit from this latent state, driven in part by the T cell receptor-stimulated translocation of active human nuclear factor-kappa B (NF-κB) into the nucleus, where it binds the HIV-1 long terminal repeat (LTR) to initiate transcription of the integrated proviral genome ([@B69]). In this context, it is notable that NF-κB is activated by a wide variety of stress responses and danger signals, including by cellular exposure to certain inflammatory cytokines or microbial-associated molecular patterns (MAMPs; also known as pathogen-associated molecular patterns, or PAMPs) ([@B83]; [@B41]). This suggests a variety of mechanisms by which co-infection might promote HIV-1 infection.

*Neisseria gonorrhoeae* Infection {#S5}
=================================

All STIs have been demonstrated to enhance HIV transmission to some degree, and the epithelial disruption induced by ulcerative STIs such as syphilis provides an obvious mechanism. Among STIs that can increase HIV-1 transmission, however, *N. gonorrhoeae* seems to have a disproportionately large effect on HIV transmission, particularly when considering that it is not an ulcerative infection ([@B30]; [@B16]). This could be mediated via enhancement of HIV infectiousness in HIV-infected ([Figure 1](#F1){ref-type="fig"}) and/or HIV susceptibility in uninfected individuals ([Figure 2](#F2){ref-type="fig"}). In terms of the former, HIV-1 infected men with gonorrhea were observed to shed ∼10-fold more virus in semen than do men without urethritis, an effect greater than that caused by other non-ulcerative STIs ([@B18]). Notably, *N. gonorrhoeae* infection had no impact on viral titers in blood, since these were not different between *N. gonorrhoeae* and HIV-1 co-infected versus HIV-1 alone control groups. However, appropriate and specific antibiotic therapy reduced semen viral shedding in the gonococcal-infected individuals to levels similar to gonorrhea-uninfected controls, suggesting that this was a localized effect that directly correlates with the mucosal gonococcal infection. The global effect of this relationship on HIV-1 spread is compounded by the fact that ∼87 million new gonococcal infections occur each year ([@B93]), allowing frequent opportunity for co-exposure in sexually active or at risk individuals.

The gonococcus is an obligately human-restricted pathogen that is highly adapted to colonize mucosal tissues, preferentially the male urethra and female endocervix, but it can also effectively colonize the nasopharynx, rectum and conjunctiva when these tissues become exposed ([@B12]; [@B73]; [@B107]). The outcome of gonococcal infection varies, ranging from an absence of any clinical signs to an intensely pathogenic inflammation manifesting as a purulent discharge composed almost entirely of polymorphonuclear neutrophils ([@B19]). These differences in outcome may depend, in part, on the physiology, tissue structure and innate immune effectors resident within the infected tissues ([@B24]; [@B107]), since male urethral infections tend to be symptomatic while female endocervical infections are less frequently so; however, asymptomatic infections can occur in men ([@B39]; [@B53]) and cervicitis does occur in a substantial proportion of women ([@B107]). Moreover, gonococcal-associated pathogenesis becomes particularly devastating when the infection ascends into the female endometrium and fallopian tubes, where it can trigger pelvic inflammatory disease (PID) with intense inflammation leading to tissue scarring, chronic pain and infertility ([@B103]; [@B59]). In humans, gonococcal PID tends to onset with abrupt and intense symptoms, often during the first 10 days after the onset of menses. Sex hormone cycling, which affects both the physiology and microbiome of the female genital tract ([@B10]), also impacts the outcome of uterine infection in a mouse model of pelvic inflammatory disease, with a marked increase in gonococcal tissue invasion and inflammation during the progesterone-dependent diestrus stage of the reproductive cycle ([@B45]). How much these differences are explained by hormonal effects on gonococcal physiology ([@B46]; [@B96]) versus the physical and immunological integrity of the mucosal barrier ([@B45]; [@B59]) remains unclear.

*N. gonorrhoeae* Pathogenesis {#S6}
=============================

Studies that have attempted to understand the impact and pathogenesis of *N. gonorrhoeae* in the context of HIV-1 co-infections are inherently challenging because both pathogens are human restricted. Our understanding of how the gonococci contribute to HIV-1 transmission must, therefore, be inferred by combining the insights gained through clinical surveillance of gonococcal and HIV-1 co-infections with those from laboratory-based models developed to study one or the other pathogen. The remainder of this review will bring these results together to develop an integrated model of how *N. gonorrhoeae* impacts HIV-1 shedding and susceptibility to HIV-1 infection, gaining insights from studies exploring the molecular and immunological processes that govern aspects of gonococcal infection with potential to impact upon HIV-1, as well as clinical studies exploring the impact of *N. gonorrhoeae* co-infection on an individual's susceptibility to HIV-1 or their likelihood to transmit the virus to their partners.

Cellular Attachment {#S6.SS1}
-------------------

*Neisseria gonorrhoeae* are not overtly pathogenic in that they do not produce protein-based exotoxins or cause direct host cellular killing, consistent with the fact that infections are often asymptomatic. Pathogenesis is, therefore, a result of neisserial replication within the tissues. To establish infection, the gonococci attach to the epithelia via their type IV pilus, which retracts to allow the bacteria to move through the mucus and establish tight secondary binding between outer membrane protein adhesins on the bacterial surface and their cognate host cellular receptors ([@B109]; [@B59]). Of these, the gonococcal colony opacity-associated (Opa) proteins have been shown to attach to members of the human carcinoembryonic antigen-related cellular adhesion molecule (CEACAM) family of surface glycoproteins, with the different binding specificities of each Opa protein variant and the varying expression of different CEACAMs on each cell type ultimately determining the outcome of this interaction ([@B95]; [@B44]; [@B115]). Transgenic mouse-based studies have established that Opa protein binding to CEACAM1 and/or CEACAM5 promotes epithelial attachment in the upper and lower female genital tract, respectively ([@B44]), while Opa binding to the neutrophil-expressed innate decoy receptor CEACAM3 promotes gonococcal engulfment and killing, and elicits a self-propagating pro-inflammatory cytokine response that drives the ongoing recruitment and activation of neutrophils to the infected tissues ([@B100]; [@B44]). Aside from these direct effects, CEACAM binding also elicits an integrin-dependent increase in epithelial cell affinity for the extracellular matrix, which reduces exfoliation of the infected cell so as to promote infection ([@B81]). The cumulative benefit of these effects presumably explains why bacteria recovered from clinical specimens tend to be expressing one or more of the phase variably-expressed Opa protein variants ([@B46]; [@B102]; [@B48]).

While CEACAM-dependent binding has been the most extensively characterized means of tissue attachment, Opa-independent interactions, including endocervically expressed CR3 binding by the gonococcal pilin-linked glycans ([@B47]) and urethrally expressed asialoglycoprotein receptor binding to gonococcal surface glycans ([@B40]), can also promote tissue association and affect a cellular response. A key challenge in understanding how the mucosal tissues respond to *N. gonorrhoeae* and, thereby, how co-infection influences HIV transmission, stems from the fact that these and other gonococcal surface ligands are both phase and antigenically variable, allowing stochastic on-off switching of their expression and alteration of the bacteria's epitope repertoire and phenotype, respectively ([@B109]). Thus, a gonococcal population may elicit different effects depending upon which adhesins (and other surface antigens) are expressed, and what cellular receptors are expressed by the infected tissues. One must remain mindful of this when interpreting laboratory-based experiments, but the contribution of this variability to the different outcomes of natural infection must also be considered since each niche will presumably select for the most fit phenotype in an ongoing basis.

Tissue Response {#S6.SS2}
---------------

The specificity of neisserial adhesins for human-derived receptors has led to considerable effort toward modeling molecular aspects of infection using immortalized cell lines, primary cells, and tissues. Classical fallopian tube organ culture studies revealed that gonococci penetrate through non-ciliated epithelia via a transcellular route to emerge into the sub-epithelial spaces ([@B71]), and caused the sloughing of adjacent (but uninfected) ciliated cells ([@B74]). More recently, primary human cervical explants have been used to reveal that infection with gonococci that do not express Opa proteins promotes dissociation of intercellular junctions to allow luminal shedding of the infected cells, while epithelia remains intact when the bacteria express CEACAM-specific Opa variants ([@B110]; [@B115]), consistent with the effects seen in human CEACAM-expressing transgenic mouse-based studies ([@B81]). When using ureter-derived tissue as a model of male urethral infection, luminally exposed cells that engulf piliated (but non-CEACAM-binding) gonococci were also observed to release their intercellular junctions and be shed, thinning the stratified epithelia and exposing underlying tissues ([@B80]). Considered together, these data suggest that Opa-dependent binding to epithelial-expressed CEACAMs allows attachment and impedes the exfoliation that normally occurs as a defense against bacterial infection, thereby promoting gonococcal infection by maintaining the epithelial integrity. It is notable in this regard that the transitional zone between the ectocervix and endocervix displays very little CEACAM expression and allows gonococcal penetration regardless of their Opa protein expression ([@B115]), suggesting that this region may be particularly susceptible to gonococcal-induced epithelial thinning to promote exposure to underlying HIV-1 target cells.

Aside from the direct effects of *N. gonorrhoeae* on the epithelium, the inflammatory response to infection can itself interrupt the epithelial barrier. The gonococci have a curious penchant for stimulating inflammation by virtue of their ongoing release of peptidoglycan-derived NOD1 agonists ([@B60]), heptose phosphate metabolites that activate the AlpK1-TIFA innate sensor pathway ([@B34]), outer membrane "blebs" containing abundant TLR4 \[endotoxin ([@B87])\] and TLR2 \[lipoproteins ([@B29]), PorB ([@B118])\] agonists, and the type IV secretion system-mediated release of TLR9-stimulatory single-stranded chromosomal DNA ([@B89]) into the extracellular milieu. The release of these microbial-associated molecular pattern (MAMP)-containing metabolites is energetically wasteful, implying that the resulting inflammation somehow facilitates gonococcal infection, such as by allowing increased nutrient leakage into the mucosal tissues or by skewing the innate and/or adaptive immune responses so that infection can persist. Regardless, in the context of co-infection with HIV-1, pro-inflammatory cytokines such as TNF are abundantly produced upon gonococcal infection of human fallopian tube cultures, and promote cellular apoptosis and a breach in epithelial integrity ([@B79]), as well as increased HIV-1 expression in infected CD4+ T cells ([@B27]).

Beyond the effects of *N. gonorrhoeae* on HIV transmission, it is also interesting to consider that HIV-1 may influence the outcome of gonococcal infection. Inflammatory cytokines produced during the acute phase of HIV-1 infection cause a direct loss in epithelial integrity within the intestinal mucosa ([@B82]), allowing bacteria and bacterial products to pass into the tissues and cause systemic inflammation that drives further viral replication ([@B11]). Other studies have shown that interaction with HIV-1 envelope protein gp120 may itself disrupt tight and adherens junctions, causing permissiveness to infection by other viral and bacterial pathogens ([@B82]; [@B105]). This would suggest that a synergistic effect may occur, where the inflammatory response to HIV-1 would allow increased gonococcal tissue penetration, which could recruit cellular targets of HIV-1, further disrupt the epithelial barrier, and drive NF-κB-dependent HIV replication. If inflammation and/or tissue penetration are, indeed, of benefit to the gonococci, then this may facilitate infection. However, to our knowledge, there are not yet clinical or epidemiological studies to determine whether chronic HIV-1 infection promotes gonococcal infection or disease.

Gonococcal-Specific Effects on HIV-1 Target Cell Populations {#S7}
============================================================

The hallmark of a gonococcal infection is the pathogenic recruitment of neutrophils to the site of infection, leading to a purulent discharge that results from this prolonged and inappropriately exuberant neutrophil recruitment. Despite this intense inflammatory response, there is curiously little evidence of an adaptive response to gonococcal infection. The answer to this conundrum appears to stem from the Th17-biased response to gonococcal infection, at least in the case of lower genital tract infection in female mice. Specifically, gonococcal infection leads to marked expression of the Th17-related IL-17 and IL-22, without any concomitant appearance of Th1 or Th2 cytokines, or of gonococcal-specific antibodies. When IL-17 signaling was blocked with IL-17-specific antibodies or in IL-17 receptor-deficient mice, neutrophil recruitment decreased and the gonococcal burden increased, implying that IL-17-driven effects combat the infection ([@B25]). However, strikingly, the administration of TGFβ-specific antibodies during primary gonococcal infection effectively inhibited the Th17 response (because TGFβ drives Th17 differentiation in mice) but allowed the emergence of a gonococcal-specific adaptive response that protected against re-infection ([@B64]). A protective memory response could also be elicited by blocking IL-10 signaling ([@B65]) or by the administration of microencapsulated IL-12 ([@B66]) during the primary infection. Considered together, these studies suggest that the gonococci have evolved to persist during the Th17-driven inflammation, with the benefit being that this highly polarized response prevents the individual from becoming immune to the infection. What remains unclear is whether this Th17 response is an inherent bias of the female genital tract or whether the gonococci have properties that elicit this outcome, such as through their ongoing and profuse release of MAMPs discussed earlier in this review. Regardless, this effect may directly influence HIV-1 transmission because activated Th17 cells are the primary target for this virus during acute mucosal infection ([@B36]; [@B86]; [@B2]; [@B72]), and may indirectly affect virus susceptibility if HIV-specific adaptive responses were to be inhibited.

Innate Activation of HIV-Infected CD4 + T Cells {#S7.SS1}
-----------------------------------------------

The disparate effects that CD4+ T cells may have on host immune protection, exemplified by the opposing outcomes of Th17 and Th1 effector responses on gonococcal infection discussed above, makes it somewhat foolhardy to try and difficult to extrapolate from cell-based *in vitro* studies to predict the global outcome of infection *in vivo*, particularly considering the central role that these cells play as both a cellular HIV target and drivers of host immunity against HIV infection. Nevertheless, it is reasonable to consider the effect of co-infection on a cellular level. Given that NF-κB-driven transcription is the most dramatic outcome of cellular activation in response to microbial-derived immune agonists, and that this transcription factor governs expression from the HIV-1 LTR, this is an obvious potential link between co-infection and HIV-1 replication. As noted above, pro-inflammatory cytokines expressed by gonococcal-infected genital epithelial cells provoke LTR-driven HIV expression in an NF-κB-dependent manner ([@B27]), revealing an indirect effect that should be shared by any inflammatory stimuli. A more direct effect on HIV-1 replication is apparent with gonococcal-derived TLR2 agonists, which promote HIV-1 uptake and nuclear import of viral DNA in resting primary human CD4+ T cells ([@B22]). Notable in this regard, gonococcal-derived endotoxin (a TLR4 agonist) does not have a similar effect, consistent with the fact that most other TLRs are not expressed by human CD4+ T cells ([@B22]; [@B67]).

Once latent HIV-1 infection has been established, gonococcal infection will elicit a robust viral LTR-dependent transcriptional response. This effect occurs independent of any TLR (or NOD) receptors, and can be elicited by simple exposure of the latently infected CD4+ T cells to bacterial-free culture supernatants from *N. gonorrhoeae*, but does not occur in response to culture supernatants from non-neisserial bacterial species ([@B13]; [@B67]). This activity is due to the peculiar propensity for pathogenic and commensal *Neisseria* species to release heptose phosphate-containing metabolites from the ADP-heptose pathway, a biosynthetic cascade that normally leads to the incorporation of heptose into the inner core of gram negative lipopolysaccharides ([@B67]; [@B34]); other bacteria effectively sequester heptose phosphates within their cytoplasm ([@B34]). These 7-carbon phosphorylated sugars activate innate immune responses in mammalian cells independent of canonical pattern recognition receptor-mediated signaling. Instead, they are directly bound by the cytosolic alpha kinase 1 (AlpK1). Heptose phosphate binding activates the kinase so that it can phosphorylate TIFA, which then self-associates into large cytosolic TIFAsome structures that function as a scaffold to drive NF-κB-mediated transcription ([@B34]; [@B76]; [@B1]; [@B117]). Heptose phosphates therefore provide a direct link between gonococcal infection and HIV-1 replication in CD4+ T cells by the virtue of NF-κB activation through TIFA-AlpK1 axis.

CEACAM1-Mediated Suppression of T Cell Responses {#S7.SS2}
------------------------------------------------

While innate drivers of inflammation stimulate HIV-1 transcription, gonococcal Opa protein binding to human CEACAM1 can broadly suppress CD4+ T cell responses to T cell receptor engagement and certain other activating stimuli ([@B9]). Very little CEACAM1 is apparent on resting lymphocytes, but its expression is upregulated upon cellular activation. Unlike other immune cells, CD4+ T-cells are unable to engulf gonococci that attach to their surface, leading to a stable association between Opa protein-expressing gonococci and CEACAM1 on the cell surface ([@B58]). When the T cell receptor becomes engaged by antigen presenting cells, it would normally unleash a kinase-dependent signaling cascade that activates the T cell. However, when CEACAM1 is engaged by gonococci ([@B58]) or gonococcal-derived outer membrane blebs ([@B57]), tyrosine residues within the immune receptor tyrosine-based inhibitory motif (ITIM) in the CEACAM1 cytoplasmic domain also become phosphorylated, creating docking sites to recruit SHP-1 and SHP-2 phosphatases ([@B9]; [@B37]; [@B58]). Once activated, these enzymes rapidly dephosphorylate the T cell receptor and downstream signaling effectors, shutting down the activating response ([@B9]; [@B57]). This immune inhibitory effect is compounded by the fact that Opa protein binding to CEACAM1 on DCs reprograms their maturation such that they are not able to effectively present antigen to T cells ([@B114]). In the context of HIV-1 co-infection, the hampering of T cell responses may have two different effects. First, given that the nuclear localization of NF-κB is a primary outcome of T cell receptor engagement, it seems reasonable to assume that the phosphatase activation will increase the threshold of cellular activation required to drive HIV-1 from latency. Second, the central role that CD4+ T cells play in the adaptive immune response suggests that CEACAM1 binding may suppress development of an adaptive response to the infection. While the reduced inflammation and absence of memory response may both facilitate gonococcal infection, their cumulative effect on HIV-1 infection and immunity are difficult to test given that gonococcal Opa proteins only bind human (and not mouse or other) CEACAM1.

Gonococcal Interaction With Antigen Presenting Cells {#S7.SS3}
----------------------------------------------------

Macrophage and DCs reside as sentinels within the submucosa to detect microbes infiltrating the otherwise sterile tissues, and then direct the immune responses to eliminate the invading pathogens. After capture of microbial-derived products, they migrate to secondary lymphoid organs to present foreign epitopes to T cells and thereby elicit a pathogen-specific adaptive response. Both phagocyte types express CD4 and the HIV-1 co-receptors, CXCR4 and CCR5, which facilitate viral uptake ([@B68]). However, while macrophages may be productively infected in certain contexts, DCs express innate viral restriction factors so that they rarely become infected, and produce relatively little virus when they do ([@B101]). Despite this fact, DCs are key to the establishment of infection, in part because they can project dendrites between epithelial cells and come in contact with virus as they sample the mucosal lumen, facilitating viral transport across an otherwise intact epithelial barrier ([@B68]). Further exacerbating this effect, HIV-1 binding to DC-SIGN facilitates its retention on the dendritic cell surface ([@B35]), allowing the virus to be carried to the lymph nodes and then transferred to CD4+ T cells as they engage with the phagocyte ([@B68]). Events that promote macrophage or dendritic cell sampling and/or movement to the lymph nodes, as might occur during gonococcal co-infection, would presumably facilitate this process.

While tissue resident DCs may resist infection, there is some indication that exposure to certain stimuli might affect this outcome. For instance, *in vitro* studies indicate that gonococcal co-infection of monocyte-derived DCs increases their likelihood for HIV-1 infection based upon the emergence of virally derived reverse transcriptase activity, and this effect can be reproduced through the administration of purified gonococcal PorB or lipoproteins, both of which are TLR2 agonist, or peptidoglycan ([@B116]). This study did not correlate cellular phenotype with viral expression on a single cell level, and did not quantify the proportion of cells that became infected or number of viral particles produced by the human cells, so how productive the infections were and whether the virus-expressing cells were actually DCs remains unclear. Notably, a separate study confirmed that TLR2 agonists enhanced HIV-1 production from human DCs, but also observed that TLR4 agonists instead suppressed HIV expression by virtue of their distinctive ability to stimulate production of type-I interferons, which upregulate cell autonomous immune defenses ([@B104]). Given that this study used purified agonists, it remains unknown how the combination of these and other bacterial-derived innate agonists might combine to influence HIV-1 replication *in vivo*.

Distinct from the broad involvement of conventional DCs in coordinating the adaptive response to a broad range of microbes, plasmacytoid dendritic cells (pDCs) are generally considered to be specialized for antiviral immunity ([@B68]). In this context, it is noteworthy that the gonococci unexpectedly elicit a potent pDC response, leading to a robust expression of interferon-α (IFNα), sufficient to cause a profound inhibition of HIV-1 replication in *ex vivo* cultures of peripheral blood cells from HIV-infected patients ([@B23]). Curiously, this effect is a consequence of the tendency of gonococci to liberate their genomic DNA, either by cellular lysis or their type 4 secretion system, which is detected by TLR9. At first glance, this would seem to contradict the HIV-1 stimulatory effect that has been ascribed to *N. gonorrhoeae*, however pDCs are a double-edged sword with respect to HIV-1 because the IFNα response can independently upregulate expression of viral-specific cellular defenses and recruit activated immune cells that can be infected by the virus ([@B68]). The consequences of this effect remain difficult to surmise without purposeful mucosal sampling of co-infected patients.

In contrast to DCs, tissue resident macrophages are an important latent reservoir of HIV-1 ([@B75]; [@B15]). While macrophages are typically infected following CD4 and CCR5 co-receptor engagement, CD4+ T cells remain the preferred HIV-1 target because macrophage display much lower CD4 on their surface. Viral variants that effectively target macrophage have evolved Env protein variants that bind CD4 with much higher affinity, which compensates for its low surface density ([@B5]). A recent study observed that macrophages resident within the human penile urethra can harbor integrated HIV-1, and that these produce infectious virions upon exposure to the TLR4 agonist lipopolysaccharide ([@B33]). In the context of male urethral infection by *N. gonorrhoeae*, viral shedding could then be stimulated either directly by macrophage exposure to the gonococci or their liberated products, or indirectly through the exuberant inflammatory cytokine response that is typical of gonorrhea. While yet undescribed, it seems reasonable to assume that a similar effect could occur within the female genital tract.

Beyond the stable effects of *N. gonorrhoeae* on viral replication, it is important to consider that ongoing phase variation might also cause different effects depending upon the virulence factors expressed. Notable in this regard, lipooligosaccharide (LOS) surface structures displaying terminal *N-*acetylglucosamine or *N-*acetylgalactosamine residues are detected by the C-type lectins DC-SIGN on DCs and by MGL on macrophage, respectively. These immune modulatory receptors have the potential to alter the phagocytic responses to other activating stimuli. Consistent with this, gonococcal isolates expressing different LOS structures were found to elicit modest but significant differences in the pattern of cytokines expressed upon *in vitro* infection of these phagocytes, leading to speculation that the adaptive response may skew toward a Th1, Th2, or Th17 bias depending on what phase variable glycan structures are present ([@B108]). As discussed above, phase variable Opa protein-dependent binding to CEACAM1 expressed by DCs can also effectively suppress their maturation in response to activating stimuli including gonococcal infection, preventing the cells from stimulating both CD4+ T cell and CD8+ T cell responses ([@B114]). It is enticing to think that these effects may have contributed to the observed Th17 immunological bias that suppresses a protective memory response in the mouse lower genital tract infection studies described above. However, whether these differences actually influence the global immune response to *N. gonorrhoeae* and/or HIV-1 during mucosal infection remains to be explored.

The Confounding Effect of Antimicrobial Peptides {#S7.SS4}
------------------------------------------------

It seems intuitive that HIV-1 may benefit from the gonococcal effects aimed at actively suppressing or misguiding otherwise effective immune defenses, or from stimulating an inflammatory response that drives viral expression. However, *N. gonorrhoeae* also triggers the release of neutrophil and epithelial-derived antimicrobial peptides during female genital infection ([@B112]) and gonococcal urethritis in men ([@B85]). In fact, increased recovery of neutrophil-derived peptides in vaginal swabs is a highly sensitive marker for endometritis among women infected with *N. gonorrhoeae* ([@B112]). While the gonococci can resist most cationic peptides through a combination of lipid A modification and/or efflux pump expression ([@B49]), their effect on HIV-1 susceptibility *in vivo* is not so clear. For example, while HIV-1 tends to be susceptible to many antimicrobial peptides *in vitro*, either directly or via activation of innate cellular responses ([@B54]; [@B31]), but α-defensins 5 and 6 have been shown to enhance the infectivity of CCR5-tropic HIV-1 by promoting viral aggregation and attachment to the target cell surface ([@B55]; [@B90]). Notably, many antimicrobial peptides are secreted in a propeptide form that must be processed by neutrophil-released proteases ([@B85]). Therefore, the relative expression of different peptides and local density of neutrophils, which is obviously high during gonococcal-induced inflammation, is a delicate balance that in theory could combine to either facilitate or inhibit HIV-1 infection. Unfortunately, it seems that the balance is tilted toward increased HIV susceptibility: despite the fact that increased genital levels of α-defensins and cathelicidins (LL-37) were associated with an increased ability of genital secretions to neutralize HIV *ex vivo*, these increases were also associated with increased subsequent HIV acquisition in both women ([@B63]) and men ([@B42]).

Gonococcal Effects on the HIV-1 Specific Adaptive Response {#S8}
==========================================================

In women, cervicitis is evident as a purulent discharge consisting almost entirely of neutrophils. While the numbers are smaller, it is notable that there is a significant increase in endocervical CD4+, CD8+, and γδ T cells during uncomplicated gonococcal infection regardless of whether cervicitis is apparent or not ([@B62]). These effects are a highly localized in that there is no difference in the number of leukocytes in ectocervical or vaginal specimens taken from women with or without *N. gonorrhoeae* infection ([@B62]), and they do not result from a global increase in systemic lymphocyte counts, which don't significantly change during gonococcal infection ([@B52]). It remains unclear whether the apparently targeted recruitment of leukocytes reflects differences in gonococcal attachment or penetration through the epithelial barrier at the endocervix, or whether there are distinct inflammatory responses by epithelia along the genital tract. Regardless, considering that the endocervix is considered to be the prime site for infection with HIV-1, this suggests an obvious site for direct and indirect interactions to occur.

Despite the localized nature of uncomplicated gonococcal infection, there are systemic effects of gonorrhea. Most notably, HIV-1 viremia increases during gonococcal cervicitis ([@B3]). While the number of T cells does not change in blood, functional studies suggest that a smaller proportion of HIV epitope-specific CD8+ T cells express IFNγ during gonococcal infection than do after the bacterial infection is treated ([@B52]). This appears to be a global effect as a similar reduction in responses to CMV epitopes was also apparent ([@B52]), and may reflect a systemic skewing of the T cell response rather than a global suppression of immunity ([@B3]). The effect of gonococcal infection is transient in that any effects on lymphocyte response, systemic HIV-1 load or localized viral shedding abate once the bacterial infection is cleared.

Given the chronic nature of HIV-1 infection, clinical studies understandably tend to explore the interactions between *N. gonorrhoeae* and the virus by monitoring changes (or lack thereof) when HIV-infected individuals acquire a gonococcal infection. A rare opportunity to describe the effects of gonococcal infection on HIV-specific immune responses occurred during a large HIV-1 prevention trial involving high risk HIV-negative female sex workers in Nairobi, Kenya, since it involved monthly screening for STIs, including gonorrhea ([@B99]). Thirty five of 466 participants acquired HIV-1 during the course of this trial. Quite unexpectedly, the intensity and breadth of HIV-specific CD8 T-cell responses were significantly higher in female sex workers who acquired HIV-1 during a period in which they had a gonococcal infection relative to that apparent in women who were not co-infected ([@B99]). This difference was not simply due to increased viral shedding by the transmitting male partner, since *Chlamydia trachomatis* and *Trichomonas vaginalis* also cause urethritis in men but coincident infection with these did not have a similar immune-enhancing effect. Given that gonococcal co-infection did not appear to influence the viral load setpoint once infection is established ([@B99]), and that individuals within this cohort have a 5-fold increased risk of acquiring HIV-1 ([@B50]), the increased CD8 response was not protective. Instead, it seems reasonable to consider that the increased adaptive response may stem from a combination of higher exposure from the gonococcal-infected seminal fluid and an increased susceptibility of the female partner, perhaps due to the gonococcal-dependent recruitment of target cells into the genital tract or disruption of the epithelial barrier, leading to a higher acute exposure to the virus. In this case, the increased susceptibility and increased immune response may effectively offset each other.

Modeling the Mucosal Response {#S8.SS1}
-----------------------------

The relationship between *N. gonorrhoeae* and HIV-1 are complex, and the observational nature of clinical studies prevents the assignment of causality to any effects seen. Models intended to understand molecular and immunologic interactions between the pathogens are difficult to establish, since both *N. gonorrhoeae* and HIV-1 are human-restricted pathogens. Indeed, gorilla, orangutan and chimpanzees may be the only hosts that these two pathogens might naturally co-infect ([@B70]; [@B38]), and these are neither financially or (more importantly), ethically reasonable models. However, the recent advent of highly elegant mouse models for the study of HIV-1 provides an opportunity to explore some aspects of co-infection. In particular, the engraftment of human CD34^+^ fetal liver or umbilical cord-derived blood stem cells into highly immunodeficient NSG (NOD/*Ltsz-scid*/*scid*γ*c*^*null*^) mice allows reconstitution of a leukocyte pool that is human-derived, allowing chronic HIV-1 infection of the human CD4+ T cells ([@B21]). When these mice were vaginally challenged with *N. gonorrhoeae*, they displayed increased shedding of HIV-1 in genital secretions ([@B113]). This response occurred without a concomitant increase in systemic viremia, suggesting that the gonococcal infection was stimulating local HIV-1 production within cells of the genital tract. While this model is not trivial to establish, it provides a tractable system to gain mechanistic insight and explore novel therapeutic interventions.

Conclusion {#S9}
==========

Sexually transmitted infections have been referred to as a hidden epidemic ([@B43]; [@B16]), both because they are not openly discussed due to stigma, and also because they may be asymptomatic in over 80% of cases and so are infrequently recognized as an STI since a prospective study of women who are at high risk of HIV acquisition found that only 12.3% of women infected with a pathogen known to cause vaginal discharge had any signs or symptoms of infection ([@B78]). Thus, even though these co-infections are currently treatable, they continue to drive HIV transmission while they smolder undetected due to stigma and under-diagnosis. This situation is exacerbated in the case of *N. gonorrhoeae* since the recent emergence of multi-drug resistant isolates may soon reduce our ability to effectively treat the infection ([@B111]). In the absence of an HIV vaccine on the horizon, it is reasonable to consider that interventions targeting these co-pathogens and other pathogens that facilitate HIV transmission may represent one of the achievable short to medium-term strategies to reduce the spread of HIV-1. Considering the substantial impact that gonorrhea in particular has on HIV transmission within a population, further studies aimed to understand the molecular and immunologic determinants of this interaction will hopefully reveal new prevention avenues. A vaccine that confers sterilizing immunity against *N. gonorrhoeae* is a particularly enticing goal when considering that this bacterium does not live outside of humans, which suggests that it could be eradicated. Despite political and economic barriers to the implementation of interventions against STIs will always be contentious, the potential for a lasting positive global health impact on two major pandemics means that there is no better time than the present to get this work underway.
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